NINathalie Ialy-Radio

Nathalie Ialy-Radio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nathalie Ialy-Radio has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PhysiofUS : a tissue-motion based method for heart and breathing rate assessment in neurofunctional ultrasound imaging

    by Nicolas Zucker, Samuel Le Meur-Diebolt, Felipe Cybis Pereira, Jerome Baranger, Isabella Hurvitz, Charlie Demené, Bruno Osmanski, Nathalie Ialy-Radio, Valérie Biran, Olivier Baud, et al.

    Recent studies have shown growing evidence that brain function is closely synchronised with global physiological parameters. Heart rate is linked to various cognitive processes and previous research has also demonstrated a strong correlation between neuronal activity and breathing. These findings highlight the significance of monitoring these key physiological parameters during neuroimaging as they provide valuable insights into the overall brain function. Today, in neuroimaging, assessing these parameters required additional cumbersome devices or implanted electrodes. In this work, we performed ultrafast ultrasound imaging both in rodents and human neonates, and we extracted heart and breathing rates from local tissue motion assessed by raw ultrasound data processing. Such ‘PhysiofUS’ automatically select two specific and optimal brain regions with pulsatile tissue signals to monitor such parameters. We validated the correspondence of these periodic signals with heart and breathing rates assessed using gold-standard electrodes in various conditions in rodents. We also validated Physio-fUS imaging in a clinical environment using conventional ECG. We show the potential of fUS imaging as an integrative tool for simultaneously monitoring physiological parameters during neurofunctional imaging. Beyond the technological improvement, this innovation could enhance our understanding of the link between breathing, heart rate and neurovascular activity both anesthetised in preclinincal research and clinical functional ultrasound imaging.

  • Open Access

    Development of a novel, non-invasive and whole brain biomarker of demyelination in a mouse model of multiple sclerosis

    by Benoit Beliard, Lauriane Delay, Isabelle Rivals, Youenn Travert-Jouanneau, Nathalie Ialy-Radio, Annabelle Réaux-Le Goazigo, Thomas Deffieux, Daniel P. Bradley, Mickael Tanter, Sophie Pezet

    Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system (CNS), affecting 2.8 million people worldwide, that presents multiple features, one of which is demyelination. Although treatments exist to manage the condition, no cure has been found to stop the progression of neurodegeneration. To develop new treatments and investigate the multiple systems impacted by MS, new imaging technologies are needed at the preclinical stage. Functional ultrasound imaging (fUS) has recently been demonstrated to robustly measure brain cerebral blood volume (CBV) dynamics as an indirect measure of neural activity. This study aimed at proposing a new biomarker of de- and/or re-myelination in a mouse model of MS induced by cuprizone. We demonstrate first that extended demyelination induces an increased hemodynamic response in the primary sensory cortex both spatially and temporally, which is consistent with fMRI data collected on MS patients. Second, using descriptors of the evoked hemodynamic response, we show that 3 of these descriptors allows the prediction of the level of myelin in the primary sensory cortex (p=5. 10 −5 ) and the thalamus (p=6. 10 −6 ). The development of such a non-invasive biomarker is crucial in the MS field as is provides an extremely useful tool for both disease follow-up and drug development. RESEARCH IN CONTEXT: Evidence before this study: Multiple sclerosis (MS) is an autoimmune neurodegenerative disorder of the central nervous system. It is the most common cause of neurological disability in young adults, affecting approximately 2.8 million worldwide. While the field of studies in MS has been very active at identifying the neurobiological cellular and molecular mechanisms underlying MS progression, the number of new treatments has been very limited so far, due to several factors, such as the lack of robust and non-invasive biomarkers of myelin loss in longitudinal studies (measurements during the development of the disease). Unfortunately, quantification of myelin loss, (one of the key neurobiological markers of MS progression) is classically performed post-mortem on fixed tissues, preventing longitudinal studies. Longitudinal follow up of an indirect measure of myelin loss is possible, using magnetic resonance imaging. However, the small size of rodent brains poses a challenge for conventional imaging techniques, requiring the use of high field magnet to achieve the necessary sensitivity and resolution. Added value of this study: In this study, using a sensitive neuroimaging technique, we developed a simple, non-invasive, predictive biomarker able to quantify the individual amount of myelin content consistently and accurately in brain structures in mice. Implications of all the available evidence: The development of such a biomarker is extremely important for the MS field as it will accelerate the pre-clinical tests for drug efficacy. The benefits provided by our biomarker encompass: 1) Enhanced sensitivity in individually quantifying myelin content, providing a more comprehensive assessment across diverse brain regions 2) Speeding up the process of the discovery, by reducing the number of animals required per group and 3) It will also likely lead to new scientific outcomes, as many more structures will be studied (most teams and drug compagnies only study the demyelination at the level of the corpus callosum). Finally, from a clinical perspective, given the brain alterations observed in this animal model closely mirror those observed in early stages in patients with MS, we anticipate our biomarker, with minimal additional refinements, to be readily applicable in clinical settings.